Background: QALYs combine survival and health-related quality of life (QOL)
The Australian Pharmaceutical Benefits Sched-an economic evaluation and the estimated impact on ule (PBS) aims to provide reliable and affordable government health budgets. The PBAC, with the access to a wide range of necessary medicines for assistance of its subcommittees, appraises each subAustralian residents and eligible visitors through mission and makes recommendations for governgovernment subsidies.
[1] For a pharmaceutical or ment funding, defers the submission or rejects the vaccine to be listed on the PBS, a sponsor prepares a submission. Decisions to recommend are presented detailed submission according to guidelines.
[2] Sub-to the Minister for Health for approval. Decisions to missions are considered by the Pharmaceutical Ben-defer are those where the evidence in the submission efits Advisory Committee (PBAC), an independent might be accepted in principle but the price of the statutory body established to make recommenda-medication requires negotiation and/or further infortions to the Minister for Health on which pharma-mation is required. Following rejection, a sponsor ceuticals should be subsidized by the Australian may resubmit the drug for consideration at a subseGovernment. In January 1993, Australia became the quent meeting; it is expected that the sponsor might first country to require an assessment of the costs present new clinical evidence, lower the price and/or and cost effectiveness as part of the decision-making undertake major revisions to decision modelling process for government subsidies of medications. [2] (e.g. including providing more relevant cost and/or As such, the PBAC process is one of the most quality-of-life [QOL] data). Although economic efdeveloped in the world. ficiency is not the sole factor considered in reimbursement decisions, the importance placed on this The PBAC considers each submission on the highlights the need for a consistent approach to basis of safety, efficacy, cost effectiveness and the economic evaluation. clinical role of the new pharmaceutical relative to a comparator. [2] Sponsors of pharmaceuticals are reOne type of economic evaluation, cost-utility quired to provide details on the pharmaceutical (ac-analysis (CUA), uses the QALY as its outcome tion, indications and restrictions, treatment details, measure. The QALY has gained popularity as the main comparator, clinical management), a clinical outcome measure of choice for economic evaluaevaluation of the main indication (including a tions of healthcare interventions. Underlying the systematic review of all relevant randomized trials), QALY measure is a common assumption that Use of QALYs in PBAC Submissions 299 healthcare resources should be allocated in such a able properties in a measure of health outcomes for way as to maximize any health gains in society as making decisions around the funding of healthcare measured by additional QALYs. [3] That is, utilitari-interventions.
[3] HR-QOL scores that do not indicate anism weights the health gains of each individual strength of preference have less intrinsic validity. equally to maximize any increase in the level of
To calculate QALYs is a straightforward process. health of society. Therefore, all else being equal, for The duration a person is in a health state is multia given budget, programmes that provide more addi-plied by the QALY weight for that health state. tional QALYs should be given priority for funding People may experience many health states throughover programmes that produce fewer additional out life; as such, the products of QALY weights and QALYs.
(expected) duration for each health state are Since April 2004, QALYs have been required by summed to give QALYs. There are two main apthe National Institute for Health and Clinical Excel-proaches to obtaining QALY weights to calculate lence (NICE) in the economic evaluation of all QALYs: healthcare interventions being appraised.
[4,5] How-1. using a multi-attribute utility instrument (MAUI); ever, the US FDA appears to be avoiding the con-and cept of QALYs and has rebadged health-related 2. creating scenarios to elicit QALY weights QOL (HR-QOL) under a banner of patient-reported through health state valuation (HSV) experiments. outcomes (PROs). [6, 7] In its latest guidelines, the MAUIs have three key elements: (i) a generic PBAC has described QALYs and their use in sub-QOL instrument; (ii) a scaling technique (based on a missions.
[2] A summary is provided here. stated preference task, such as a time trade-off QALYs have three key characteristics:
[TTO] and standard gamble [SG]) reflecting trade-1. They combine survival and HR-QOL into a single offs that individuals representative of society are measure that allows comparability across healthcare willing to make between health outcomes (i.e. prefprogrammes with disparate health outcomes. [8] erence-based rankings of health states); and (iii) a 2. Each health state is assigned a preference-based mathematical or statistical model that provides a QOL weight, or 'QALY weight'.
[9-11] 1 The QALY scoring algorithm to generate QALY weights for weight indicates how much of a life-year a person any health state that can be described by the instruwould be prepared to sacrifice to improve their QOL ment. The QOL instrument consists of a questionfrom a given health state to full health. It is mea-naire that breaks down a health state into (multiple) sured on a cardinal scale such that a year of life in attributes, each of which corresponds to one or more perfect health has a score of one and death has a questions and responses in the instrument. Rescore of zero. Scores less than zero, to reflect states sponses are scaled and the mathematical model worse than death, are possible. combines these attribute scores into an overall instrument score. 3. QALY weights are derived from individuals in stated preference tasks that are designed to reflect MAUIs allow health state experiences to be dethe individual's trade-offs between quality and scribed by patients using a common HR-QOL inquantity of life (weights derived from a visual ana-strument, in an environment that minimizes bias in logue scale [VAS] are not considered valid in Aus-the reporting of that experience; MAUIs also assign tralia). [2] 'strength of preference' from the general population As such, there is some validity to QALYs repre-(i.e. a valuation) associated with the health states. In senting social trade-offs and values, which are desir-this way, MAUIs are an appropriate and practical 1 We use the term 'QALY weight' to distinguish the weights used to estimate QALYs from the scoring systems commonly used in QOL instruments, such as the Short-Form 36-item health survey (SF-36). The scores for the latter are not based on any direct measurement of individual preferences, and hence there is no indication of strength of preference for different health states, or for the trade-offs individuals may make between dimensions of HR-QOL that contribute to the instrument. Elsewhere, QALY weights are sometimes referred to as utilities or utility weights, and are claimed to have a basis in Von Neumann Morgenstern expected utility. However, QALYs are only a measure of utility if additional strong restrictions are imposed on the utility function.
method to obtain preference-based valuations for While debate continues about methods for deriving QALYs, there is general agreement that QALYs, HR-QOL. MAUIs, along with disease-specific meaas a measure of health benefit, should have a sound sures, can be used in clinical trials to collect inforbasis in measurement of individuals' relative prefermation at baseline and at various time points during ences for health states such that they capture the follow-up.
values of society as a whole. [22] [23] [24] Recognizing the There are several well known MAUIs available need for consistency, NICE and the US Panel on that possess the three key elements; the most recent Cost Effectiveness in Health and Medicine have is the SF-6D developed by Brazier and col-produced reference cases for undertaking economic leagues [12, 13] to transform SF-36 or SF-12 scores into evaluation for pharmaceuticals and healthcare inter-QALY weights. The most widely used is the ventions. [4, 25] Both reference cases suggest the use of EQ-5D; [14, 15] others include the Health Utilities In-choice-based techniques to elicit preferences, the dex (HUI2 and HUI3) [16, 17] and the Assessment of use of generic MAUIs to describe and value health Quality of Life (AQOL). [18, 19] These MAUIs are all states, and the use of a representative sample of the based on acceptable scaling techniques using the SG public as the most appropriate source for preferor TTO methods. [8, 20] The comparative merits of the ences. This approach is now also encouraged in the SG and TTO techniques have been the subject of most recent version of the PBAC guidelines some debate; however, there appears to be no estab-(2006). [2] lished compelling normative or empirical reason to This descriptive study investigates the methods favour the SG over the TTO method or vice ver-used for estimating QALY weights included in subsa. [8, 21] Similarly, no single MAUI has demonstrated missions from industry to the PBAC for listing on unequivocal superiority or universal acceptance. [2] the PBS, prepared according to previous versions of Moreover, there is variation between scores derived the PBAC guidelines, which neither encouraged nor from MAUIs; [18] this variation may be due to the discouraged CUA. We review the submissions that preferences of the population valuing the health have reported QALYs as a measure of health outstate, cultural differences and differences in the con-comes with the purpose of identifying the approach struction and domains of the instruments.
taken to obtain QALY weights, assessing whether this approach involved the use of MAUI or HSV An alternative to using a MAUI is the use of HSV experiments for scaling the health states, and identiexperiments. In HSV, stated preference experiments fying the population from whom the QALY weights around health state scenarios are undertaken to elicit were obtained. We do not assess the strengths and QALY weights. The scenarios are often hypothetiweakness of each of the various MAUIs or the cal, and the respondents may be patients or drawn different HSV techniques to elicit preferences (e.g. from a community sample. The stated preference we do not compare TTO with SG). In addition, we experiments generally involve an explicit trade-off assess whether the approach used has any bearing on between health profiles described by HR-QOL and the PBAC's decision to recommend or reject the survival durations. The TTO and SG have been the submission. Notably, submissions may include both most commonly used approaches for HSV experia cost-effectiveness analysis (CEA) and CUA to ments. Such experiments generally involve face-tosupport their case. Thus, the PBAC may place greatface interviews requiring numerous decisions by er weight on the CEA if the quality of the CUA is participants to identify their preferences. These can low, or may assess the CEA results as being less be relatively labour-intensive and sometimes cogniuncertain than the CUA results. tively challenging. Rating scales (such as a VAS) have been appealing because they are easy (and Methods inexpensive) to use, but they do not involve a choice or a trade-off to be made between HR-QOL and
The database of submissions considered at PBAC survival, and therefore it can be argued that the meetings was obtained from the Pharmaceutical relative strength of preference can not be inferred Evaluation Section (PES) of the Australian Governvalidly.
ment Department of Health and Ageing (DoHA).
All submissions considered by the PBAC at their eral population are a random (and potentially repremeetings between January 2002 and December sentative) sample of society. 2004 that reported QALYs as an outcome measure Where the submission relied on data from pubwere included for this analysis. Further information lished literature, the primary study was retrieved. on each included submission was obtained in the Where more than one of the above approaches to form of the PES commentary on the submission. estimate QALY weights was used in a submission, These commentaries are prepared by expert analysts the approaches were analyzed separately. For examwho make detailed critical reports on each submis-ple, if a submission used a MAUI and an HSV sion.
experiment to derive QALY weights, both were recorded and considered independently. Similarly, Included submissions were sorted according to when an approach was used in more than one popuwhich of the following approaches were used to lation group (e.g. an HSV experiment was underobtain QALY weights:
taken by the general population and a group of 1. use of a MAUI; patients), each population group was recorded and 2. use of an HSV experiment in response to health considered separately. state scenarios;
The approach and the population were then clas-3. non-preference-based approaches.
sified as 'more appropriate' and 'less appropriate'. We extracted data from the commentaries on the The 'more appropriate' approaches were where a submissions, focusing on the approach used to ob-MAUI was administered to patients who were curtain QALY weights. When a MAUI was used, derently experiencing the health states being valued, or tails of the instrument and the population completwhen an HSV experiment (such as a TTO or SG) ing the questionnaire were recorded. Where an apwas undertaken in either the general population to proach involved HSV experiments around health value a health state derived from clinical and QOL state scenarios, the technique and population from studies or a population of patients to value their own whom preferences were elicited were recorded. Fihealth state. All other approaches were considered nally, details were noted for non-preference-based 'less appropriate'. We also sorted data into 'recomapproaches, including rating scales and mapping mend', 'reject' or 'defer' according to the outcome transformations. We have included mapping transfrom the PBAC meeting. formations in this category where the mapping funcData submitted to the PBAC was bound by secretion involved mapping a disease-specific or generic cy provisions in the National Health Act 1953 so it is HR-QOL scale onto a 0-1 scale, where derived not possible to name the pharmaceuticals or indicascores did not involve trade-offs for preference elicitions requested in the submissions. However, we did tation (e.g. mapping SF-36 scores onto the quality of disaggregate results according to a general category well-being index [26] ). Likewise, rating scales (e.g. indicated for the use of each medication. VAS) do not require a trade-off or choice decision to be made. As such, scores from these approaches are not consistent with the QALY approach, which exResults plicitly trades off QOL and survival.
Populations from whom QALY weights were The PES database contained 230 unique submisobtained were categorized as follows: sion numbers that were considered by the PBAC at 1. target patient group meetings during 2002-4. A total of 49 (21%) sub-2. healthcare professionals missions were identified that included QALYs 3. investigators (table I) , and these were included in this study for 4. general population.
further consideration. There was no apparent trend in the proportion of submissions reporting QALYs, The target patient groups are living with or being with 18%, 27% and 19% in 2002, 2003 and 2004 , treated for the disease, and include those actively respectively. taking the study medication or those in a clinical trial. Healthcare professionals include clinicians,
The 49 submissions with QALYs consisted of nurses and allied health professionals, and the gen-new submissions (27%), resubmissions (51%), sub-(39%) and 24 (36%) of the approaches, respectively. Non-preference-based approaches accounted for 16 (24%) of all approaches used. When a specific study was undertaken for the purposes of a submission, MAUIs were most frequently used (12/19; 63%) followed by non-preference approaches (5/19; 26%), and two (11%) undertook an HSV experiment.
Of the MAUIs used (n = 26), the EQ-5D was the most common (15/26; 58%), followed by the AQOL (6/26; 23%) and the relatively new SF-6D (3/26; 12%) [table II]. Of the HSV experiments, the TTO was used in 14/24 (58%), SG in 5/24 (21%) and both TTO and SG were used in 5/24 (21%) of the ap- proaches. The five approaches referring to combined use of the TTO and SG all referred to one missions for a change to listing (12%) and other paper in the published literature; [27] however, the submissions such as deferred PBAC considerations details of how the TTO and SG were implemented and submissions in response to pricing matters and combined were not reported in that paper.
Five of the 49 submissions identified had insuffiOf the non-preference-based approaches, mapcient information available to allow analysis of the ping functions and rating scales were each employed approaches used to derive QALY weights and were in 7/16 approaches (44%), with consensus opinion therefore excluded from further analysis. Of the and an unvalidated instrument in the remaining 2/16 preference source(s) and methodology used in the (12%). All mapping functions were developed from 44 submissions with data available, 11 used more regressions to transform a QOL measure onto a 0-1 than one approach and two presented four approach-scale. A published algorithm was used twice [26] and es. Overall, there were 66 approaches reported from two approaches developed algorithms specifically 44 submissions. Of the 66 approaches used in the for the submissions. Use of non-preference apsubmissions, 47 (71%) were taken from studies pre-proaches, including global QOL scores and VAS, viously published in academic journals; the remain-were relatively more common in specific studies ing 19 (29%) presented studies specifically under-than in approaches drawn from the literature, i.e. 8/ taken for the purposes of preparing a CUA to in-19 (42%) vs 8/47 (17%), respectively. clude in submissions to reimbursement agencies. Of Rejection rates were greatest for submissions these 66 approaches used in the submissions, 16 with non-preference approaches (11/16; 69%) fol-(24%) resulted in a positive recommendation for the lowed by HSVs (15/24; 63%) then MAUIs (14/26; drug, ten (15%) were deferred and 40 (61%) were 54%). Submissions using HSVs were most likely to rejected.
be recommended (8/24; 33%) and submissions using MAUIs most likely to be deferred (7/26; 27%).
Approaches Used
Surprisingly, 3/16 (19%) non-preference approaches were associated with positive recommendations MAUIs and HSV experiments were the most frequently employed approaches, accounting for 26 (table II) .
2 A resubmission is a submission that was previously rejected by the PBAC; the sponsor may choose to resubmit to provide additional information and/or make other appropriate amendments. The main reasons for rejections typically include insufficient evidence on the clinical benefit (e.g. from a different target population from that described in the evidence provided), too much residual uncertainty around the clinical benefit or cost-effectiveness estimate, or an unacceptable cost-effectiveness ratio.
Use of QALYs in PBAC Submissions
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The Participants HSV experiments were sourced from published studies.
In the non-preference-based approaches, patients Of the 66 approaches used, six sampled from were the most common group reporting 'QALY more than one population group. When a MAUI was weights' (8/16; 50%), followed by investigators (4/ used, patients with the relevant condition completed 16; 25%), healthcare professionals (3/16; 19%) and the instrument based on their current health state in investigators plus healthcare professionals com-18/26 (69%) occasions (table III) ; 8/26 (31%) were bined (1/16; 6%). completed by proxy (or a combination of patients Overall, QALY weights derived using 'more apand proxy) based on an assessment of each health propriate' approaches were used in the majority of state. These proxies were healthcare professionals or cases (34/66; 52%). The remainder used non-preferthe investigators; in 6/26 (23%) occasions, scenarios ence approaches (16/66; 24%) or 'less appropriate' describing health states had been developed by the populations (16/66; 24%) responding to MAUIs or investigator and the proxy asked to complete the HSVs. Of the 34 'more appropriate' approaches, questionnaire. In another 2/26 (7%) of occasions, 56% were in submissions for drugs rejected by the the investigator or health professional completed the PBAC. Rejection rates were very similar between questionnaire based on their impression of the pa-MAUI and HSV methods (26% MAUI and 29% tient's health state.
HSV) and recommendation rates were the same. For those submissions that included an HSV experiment, preferences were elicited from patients on
The Clinical Indications 12/24 occasions (50%) and from healthcare professionals on 7/24 occasions (29%). The general population was used in 2/24 (8%) and were included in a Results were disaggregated into general categomixed sample in a further 2/24 (8%) of occurrences. ries based on the indicated use; 'other' was used to Most notably, there was only one specific submis-represent all categories with less than five submission that undertook an HSV experiment; all other sions in the category. Submissions for drugs to treat neoplastic disor-(both of these involved MAUIs completed by patients) and rejected all other submissions in this ders tended to use a MAUI, but with responses from category. Musculoskeletal system disorders had the healthcare professionals (table IV) ; most of these greatest number of submissions over the 2002-4 submissions were rejected. HSVs were frequently period; almost half employed a MAUI and a quarter used in submissions for infectious diseases; howused a non-preference approach to QALYs. In this ever, the response population was split between indication, most submissions used a 'more approprihealthcare professionals and patients. MAUIs and ate' approach (14/23; 61%), of which 10/14 (71%) HSVs were both used in submissions for drugs to were in submissions rejected by the PBAC. treat mental disorders, with responses more often from patients (three HSVs and three MAUIs were Half of the submissions for drugs to treat nervous completed by patients); the PBAC made one posi-system disorders (3/6; 50%) employed MAUIs but tive recommendation and one deferred decision 2/3 (67%) used responses from healthcare profes- Responses obtained from sionals; positive recommendations were made for is emphasized here that a 'more appropriate' apthe HSV with responses from patients and for a non-proach does not mean the recommendation will be preference approach with responses from clinicians. positive; however, a 'less appropriate' approach Other diseases and disorders all used responses from and/or poorly selected population may increase unpatients; 7/10 (70%) of these were 'more appropri-certainty and be a strong contributing factor to a ate' approaches, of which only 2/7 (29%) were in rejection decision. The magnitude of the cost-utility rejected submissions. ratio and the uncertainty are only two factors considered by the PBAC in their decision-making process.
Discussion
Other factors include safety, efficacy and the clinical role of the new pharmaceutical (or vaccine) The 21% of submissions to the PBAC using relative to the comparator. As a CUA was not reQALYs represents a considerable increase over the quired by the PBAC during the study period, and 2.5% found by George et al. [28] in the early 1990s.
only 21% of submissions included a CUA, it is Given the increased support for QALYs as the pripossible that obtaining QALY weights or using a mary outcome measure, particularly by the NICE, [4] 'more appropriate' approach was not given suffiand now by the PBAC, [2] it is expected this proporcient priority by the sponsor. tion will continue to rise in the future. Therefore, the comparability and appropriateness of the approachOf those submissions that did include a CUA, es and methodology used to derive QALY weights many studies used to generate QALY weights were is an important consideration.
of low quality. For example, proxies such as investiThe findings of this study suggest that, in the gators and healthcare professionals are not represenrecent period studied, there was little consistency in tative of society; likewise, non-preference-based apthe approaches and methods used to estimate QALY proaches can not reflect society's preferences or be weights in submissions considered by the PBAC. used to provide QALY weights. The inconsistencies MAUIs and HSV experiments were most widely found provide challenges for the decision-making used, accounting for 39% and 36% of the approach-process and increase uncertainty. To some extent, es used, respectively. Surprisingly, non-preference-the inconsistencies and inappropriate methods may based approaches were used in almost 24% of ap-be related to a limited amount of data being availproaches. The submissions considered in this study able to the sponsors at the time of submission. This were prepared using the guidance in the 1995 PBAC lack of appropriate data is due to a lack of foresight guidelines (and 2002 revision), which did not re-in designing clinical trials, without regard for the quire CUA, and provided limited guidance on the concurrent collection of data necessary for a good derivation of QALYs. [29] Typically, CUA was used economic evaluation (i.e. use of a MAUI and collecas a supplementary analysis to augment a base-case tion of data on resource use). Although large multi-CEA, which may have reduced the sponsor's per-national trials are often run from a centre in the US ceived necessity to obtain high-quality QALY or Europe, there is a need to allow and encourage the weights, because the PBAC may have relied prima-inclusion of local country-specific data in the data rily on the CEA as the analysis guiding their deci-collection process. Without local data, additional sion. The revised PBAC guidelines released in 2006 uncertainties are introduced when transferring reprovided more detailed guidance on QALY ap-sults to Australia, for example. Ideally, countryproaches and include a more explicit preference for specific data on resource use, costs and health out-CUA in most situations (although the use of CUA is comes would be available in adequately powered not mandatory). multinational trials; this would also allow differOverall, approaches using HSVs were the most ences between the aggregate and country-specific likely to recommended, MAUIs were the most like-results to be assessed for generalizability. In future, ly to be deferred and least likely to be rejected, and it is recommended that validated, generic MAUIs non-preference approaches were the most likely to (with the relevant country-specific scoring albe rejected. When a submission used a 'more appro-gorithm) are routinely included in all relevant compriate' approach, 56% were rejected by the PBAC. It parative randomized trials.
The most appropriate use of a MAUI for ob-they are requested to choose between. Furthermore, taining QALYs involves completion of the instru-because there are less decision points for the analyst ment by blinded participants, within a randomized in a MAUI compared with HSV (e.g. how the anatrial, to rate their own health at baseline and various lyst describes the health state) and therefore less points during follow-up using the instrument. We potential for bias and uncertainty to be introduced found that no MAUI was used in this way in submis-by the methods, MAUIs are preferred to HSV. sions to the PBAC. Most MAUIs were administered Approaches based on mapping from QOL questo (non-trial) patients with the condition under tionnaires were often inappropriate and/or lacking study, which raises some uncertainty in the validity validity, and frequently did not involve mapping a of the matching of their results to the sets of patients QOL questionnaire onto a scale where scores were taking the therapies being compared in the analysis. derived using choice-based techniques. Of particular
In some uses of a MAUI, health state scenarios concern were attempts to derive QALY weights were described for completion of the MAUI by a based on expert consensus or on an assumed linear healthcare professional or investigator. The use of a transformation of a global QOL or a rating scale to a MAUI to generate QALY weights from scenarios is QALY weight index. Weights estimated in this way inappropriate. In an extreme case, the investigator are not preference based and do not conform to the could effectively nominate the QALY weight ex-theory underpinning economic evaluation; as such pected based on his or her own opinion and then they can not be considered appropriate for use in construct scenarios aligned to the text of the MAUI. QALY calculations. Best practice would ensure that That is, it would be near impossible to describe a any transformation function would be based on data health state to a respondent without actually telling collected concurrently for both instruments in the them how to rate it on the MAUI. However, when a same population; unless this approach is taken, the MAUI is used appropriately, such as in a group of validity of any transformation is severely compatients in a randomized trial, there are numerous promized and increases uncertainty. In one submisadvantages of MAUIs, including more accurate and sion, QALY weights were transformed from the unbiased measurement of health states, comparabili-EQ-5D to the AQOL. This was unnecessary and also ty across studies (and internationally) and efficiency created greater uncertainty because the rationale for for respondents and analysts (because no MAUI doing so was unfounded; a sensitivity analysis using takes longer than 5-8 minutes to complete, and a different set of weights would have provided analysis is well developed). [2] greater elucidation of the effect of changes in those When an HSV experiment is undertaken, a weights. choice-based technique, such as the SG or TTO, When more than one approach was used, it was should be used to elicit preferences for the described often used to obtain a QALY weight for the same health states. To avoid the introduction of bias and health state. A second approach was either the same self-interest, preferences should be obtained from a technique applied to a different population, or a representative sample of society.
[2] Preferences elicdifferent technique used in the same population. The ited from representative samples of society may be additional effort needed to use two approaches could inconsistent with those of patients who may be be better spent by finding and using one technique elderly, young, from a particular social group, and with a larger relevant population. The concept of may have their preferences altered by the disease.
efficiency suggests that greater effort should go into However, preferences were rarely elicited from the obtaining greater accuracy for the main drivers, and general population, with only 2/24 (8%) using the less robust estimates may be used for those states general population exclusively and 2/24 (8%) using that have little effect (such as when there is a low a mix of patients and the general population. Inprobability of going into that health state, or the stead, subgroups of patients or healthcare profesduration in that state is short). As such, we recomsionals were commonly used for preference elicitamend that any post-trial marginal effort in obtaining tion. This reflects difficulty in ensuring that respondents adequately understand the health states that QALY weights should be directed to collecting data from patients using a MAUI or from the general missions analysed precludes definitive conclusions population using HSV.
to be made. In a previous review of submissions for inclusion The 2006 PBAC guidelines seek to minimize on the PBS (1994-7), Hill et al. [30] reported finding bias when obtaining QALY weights. [2] In the HSV examples of inappropriate questionnaire design and context, the issues are (i) how the analyst described inadequate sample size in TTO analyses. Other studthe key features of the health state(s) actually exies based on published CUAs have found extensive perienced; and (ii) how the respondent understands variation in the derivation of preferences. [31] [32] [33] The the health state from the analyst's description before findings of the current study suggest there is a then proceeding to generate the valuation via SG or general improvement in methods with increased use TTO methods. In the MAUI context, the respondent of generic MAUIs and a reduction in the use of completing the questionnaire actually understands rating scales. For example, in a review of 228 CUAs the health state, so the issues are (i) if the responinvolving 949 health state descriptions published dents are not in the randomized trial(s), how well the prior to 1997, Bell et al. [32] found that 20% of health patients completing the MAUI 'match' the patients state values were derived through MAUIs. This receiving the alternative therapies being compared; compares with 43% found in the current study. (ii) how well the questionnaire captures the elements that 'drive' the health state; (iii) how well the sepaIn contrast to earlier studies, which found the rate set of respondents in the general population Rosser Index, HUI (and its subsequent variants) and understand each health state assigned to them for Quality of Well-Being scale to be the most frequentvaluation via the SG or TTO; and (iv) how well the ly employed instruments, [31, 32] a review of 23 CUAs scoring algorithm aggregates these. Because of the undertaken alongside clinical trials (based on a MAdifficulty of minimizing investigator bias, there are UI questionnaire completed by participants in the greater concerns with HSV experiments. These fac-trial) and published between 1995 and 2002 found tors also explain the 2006 PBAC guidelines prefer-that the EQ-5D was the most common MAUI emence for MAUIs to be completed in the relevant ployed (70%) followed by the HUI and its variants double-blind randomized trials.
(26%). [34] This is similar to the findings of the current study, where the EQ-5D was used in 58% of The limitations of the current study include the all MAUIs used. assumption that all data entered in the PES database are accurate and complete, and that the analysis is
The EQ-5D is a generic, validated instrument based on the PES commentaries of submissions. The using choice-based methods for preference elicitadatabase has been independently checked and vali-tion, originally based on the preferences of a UK dated against the commentaries as part of this study. population; more recently, a scoring algorithm for Whilst there were instances when insufficient data the US population has been developed. [15] There are were available in a commentary to analyse a submis-substantial differences between the US and UK QAsion, it is considered unlikely that either the database LY weights for the same health state. For example, or commentaries would be sufficiently inaccurate to for the health state described in the EQ-5D as 11223, alter the findings of this study. While we may have the QALY weights are 0.506 and 0.255 using the US double-counted some approaches in resubmissions and UK preferences, respectively. Significant differwhere the approach used did not change, we believe ences in QALY weights between UK and Japan this is a reasonable approach to take because spon-from this instrument were evident; [35] however, sors have the opportunity to amend their approach to there were no significant differences across six estimating QALY weights; in some cases the feed-European countries.
[36] These differences in preferback from the PBAC on the original submission ences across populations create uncertainties around may have suggested that the approach should be the applicability of the QALY weights to populachanged. Despite these limitations, the data provide tions other than from whom the preferences were a reliable trend of the approaches and methodologies drawn. QALY weights for the EQ-5D and the SFused to estimate QALY weights in support of sub-6D with preferences elicited from the Australian missions. Nevertheless, the small sample of 44 sub-population are currently being developed. This will
